CPL207280
CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes[1][2].
Product Specifications
CAS Number
[2361497-72-3]
UNSPSC
12352005
Target
Free Fatty Acid Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/cpl207280.html
Purity
98.72
Solubility
10 mM in DMSO
Smiles
OC(C[C@@H](C1=CC=C(C=C1)OC/C(C)=C(C)/C)C#CC)=O
Molecular Formula
C18H22O3
Molecular Weight
286.37
References & Citations
[1]Mach M, et al. Discovery and development of CPL207280 as new GPR40/FFA1 agonist. Eur J Med Chem. 2021;226:113810.|[2]Bazydlo-Guzenda K, et al. CPL207280-a novel GPR40/FFA1-specific agonist shows a favorable safety profile and exerts anti-diabetic effects in type 2 diabetic animals[J]. Molecular Pharmacology, 2021.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6371772-01 0.1 mL
C9orf95 (NMRK1, NRK1, Nicotinamide Riboside Kinase 1, Nicotinic Acid Riboside Kinase 1, Ribosylnicotinamide Kinase 1, Ribosylnicotinic Acid Kinase 1, FLJ20559) (AP)
Ask
View Details 
MBS6371772-02 5x 0.1 mL
C9orf95 (NMRK1, NRK1, Nicotinamide Riboside Kinase 1, Nicotinic Acid Riboside Kinase 1, Ribosylnicotinamide Kinase 1, Ribosylnicotinic Acid Kinase 1, FLJ20559) (AP)
Ask
View Details GTR15320380 1 Vial
Lentiviral human C5orf47 shRNA (UAS) - Lentiviral human C5orf47 shRNA (UAS, RFP) plasmid
Ask
View Details